---
title: "Maldonado Reiterates Buy on Sutro, Sees STRO-004 Data as Proof-of-Concept and Keeps $50 Price Target Unchanged"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/295695749.md"
description: "H.C. Wainwright analyst Andres Maldonado reiterated a Buy rating on Sutro Biopharma with a $50 price target, citing STRO-004 data as proof-of-concept for the company's ADC platform despite market overreaction. He highlighted favorable safety profiles and upcoming pipeline catalysts like STRO-006 and STRO-227. LifeSci Capital also maintained a Buy rating with a $54 target."
datetime: "2026-08-12T17:15:38.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/295695749.md)
  - [en](https://longbridge.com/en/news/295695749.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/295695749.md)
generator: "portal-rs"
---

# Maldonado Reiterates Buy on Sutro, Sees STRO-004 Data as Proof-of-Concept and Keeps $50 Price Target Unchanged

Analyst Andres Y. Maldonado from H.C. Wainwright reiterated a Buy rating on Sutro Biopharma and keeping the price target at $50.00.

### Claim 55% Off TipRanks

-   Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions
-   Subscribe to TipRanks Smart Investor Newsletter, and discover new investing opportunities with data-backed stock picks

Andres Y. Maldonado has given his Buy rating due to a combination of factors, starting with his view that the market’s sharp negative reaction to the initial STRO-004 data is disproportionate to the actual clinical evidence. He argues that the early dataset, while limited, already shows a favorable safety and pharmacokinetic profile alongside initial responses in several difficult-to-treat solid tumors, supporting the potential of Sutro’s ADC platform.

Maldonado’s rating is based on the belief that the STRO-004 results provide early proof-of-concept that Sutro’s high drug-load, precisely engineered ADCs can translate as expected in humans, with manageable toxicity and dose-proportional exposure. He further highlights the upcoming clinical entry of STRO-006 and the planned IND for STRO-227 as meaningful pipeline catalysts, and therefore maintains his long-term conviction and leaves his price target unchanged at $50, reinforcing the Buy recommendation.

According to TipRanks, Y. Maldonado is a 5-star analyst with an average return of 41.7% and a 58.55% success rate. Y. Maldonado covers the Healthcare sector, focusing on stocks such as Syndax Pharmaceuticals, Verastem, and Monopar Therapeutics Inc.

In another report released today, LifeSci Capital also maintained a Buy rating on the stock with a $54.00 price target.

### Related Stocks

- [STRO.US](https://longbridge.com/en/quote/STRO.US.md)
- [SNDX.US](https://longbridge.com/en/quote/SNDX.US.md)
- [VSTM.US](https://longbridge.com/en/quote/VSTM.US.md)
- [MNPR.US](https://longbridge.com/en/quote/MNPR.US.md)

## Related News & Research

- [Why is Sutro Biopharma Stock Falling On Wednesday?](https://longbridge.com/en/news/295697857.md)
- [Sutro Biopharma: Buy Rating on Strong ADC Execution, Cash Runway Into 2028, and Multiple 2026 Catalysts](https://longbridge.com/en/news/286599325.md)
- [Bank of America Securities Keeps Their Buy Rating on Agree Realty (ADC)](https://longbridge.com/en/news/296102817.md)
- [Akari Therapeutics Builds Momentum for AKTX-101 with Compelling Urothelial Cancer Data Supporting Differentiated ADC Strategy | AKTX Stock News](https://longbridge.com/en/news/296232130.md)
- [Barclays Sticks to Its Buy Rating for Jack Henry & Associates (JKHY)](https://longbridge.com/en/news/296455498.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**